Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Conditions: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 1000

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Location: General Hospital of Northern Theater Command of Chinese PLA Shenyang Liaoning

Summary

This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.

Eligibility Criteria

Inclusion Criteria: * Patients between 18 and 80 years old, with no gender restrictions. * Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI). * Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period. Exclusion Criteria: * Expected survival time\3x ULN) and cirrhosis; * Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period; * The researchers determined that other reasons were not suitable for participants in this experiment.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06577519). StuddyBuddy aggregates publicly available trial information.